Research highlights the therapeutic potential of targeting cannabinoid receptors to counter memory impairment in early ...

Research spanning more than 20 years has led the UPV/EHU's Neurochemistry and Neurodegeneration group under Dr. Rafael Rodríguez-Puertas to discover a promising avenue for the development of new ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...

The US Food and Drug Administration approved (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults in September, making it is the first antipsychotic ...

M1 receptors, present on the cholinergic ganglia, with the role of facilitating neural transmission; M2 receptors, located on the postganglion endings of the cholinergic fibers, with the role of ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Expert Rev Endocrinol Metab. 2010;5(5):653-662.